newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

  • Praxis Precision Medicines appointed Jeffrey B. Kindler & Stuart Arbuckle to its board of directors on January 8, 2026.
  • Megan Sniecinski was promoted from Chief Business Officer to Chief Operating Officer to oversee enterprise execution & program strategy.
  • Dr. Steven Petrou was promoted from Chief Scientific Officer to President of Research & Development to lead late-stage development & commercialization.
  • CEO Marcio Souza stated the leadership changes reflect a strategic evolution focused on commercial launch planning, late-stage development, & value optimization.
  • Jeffrey B. Kindler brings prior experience as former chairman & CEO of Pfizer, with expertise in R&D transformation & strategic transactions.
  • Stuart Arbuckle joins with 13 years of experience at Vertex Pharmaceuticals, including roles in global commercial leadership & operations.
  • Board Chairman Dean Mitchell noted the new directors strengthen the board's ability to guide complex development & commercial decisions.
  • The company operates with four clinical-stage product candidates using its Cerebrum™ small molecule & Solidus™ ASO platforms.
  • Forward-looking statements regarding trial timing, regulatory submissions, & cash runway are subject to risks outlined in the press release.